Study finds a new way to shut down cancer cells’ ability to consume glucose

Many cancers depend on glucose consumption for energy, but good pharmacological targets to stop cancers’ ability to uptake and metabolize glucose are missing. CU Cancer Center study finally identifies a way to restrict the ability of cancer to use glucose for energy.

Read the rest of this entry

Important new insights into RECIST criteria measuring cancer’s response to treatment

CU Cancer Center article examines current RECIST guidelines in an effort to bring them up to speed with new complexities presented by the latest targeted therapies.

Read the rest of this entry

In the lab and in the clinic, alisertib with TAK-228 excels against solid tumors, including triple-negative breast cancer

Two CU Cancer Center studies presented this weekend at AACR Molecular Targets and Cancer Therapeutics Meeting show that using the drug alisertib along with the drug TAK-228 is more effective against triple-negative breast cancer and solid tumors than either drug alone.

Read the rest of this entry

Chemotherapy 101

Despite advances in surgery, radiation and targeted therapies, chemotherapy remains an important part of many…

Read the rest of this entry

Tarloxitinib puts tumor-seeking tail on anti-EGFR drug to precisely target lung cancer

By pairing an anti-EGFR drug with a “tail” that only activates the drug when it is very near tumor cells, tarloxitinib brings the drug to tumors while keeping concentrations safe in surrounding tissues.

Read the rest of this entry

Lung cancer driver ALK-fusion found in melanoma

Study finds a genetic change called ALK-fusion in a patient sample of a melanoma subtype called mucosal melanoma. When researchers treated a tumor grown from this sample with the drugs crizotinib and ceritinib – both FDA approved to treat ALK-positive lung cancer – the tumor responded dramatically.

Read the rest of this entry

Researchers watch in real time as fat-encased drug nanoparticles invade skin cells

CU Cancer Center study describes use of cutting-edge microscopy technology to visualize how liposomes escape from blood vessels into surrounding cells in a living mouse, offering clues that may help researchers design better drug delivery systems

Read the rest of this entry

Clinical Trials 101

If you have a complex condition, you might have heard the phrase “clinical trial” at…

Read the rest of this entry

Promising phase 1/2 results for entrectinib against ROS1+ non-small cell lung cancer

We are hopeful that entrectinib will help us control many cases of ROS1+ lung cancer in both the body and the brain,” says Robert C. Doebele, MD, PhD.

Read the rest of this entry

P53 “master switch” remains top target in gene signaling network controlling cancer suppression

“There are few things that are as relevant across cancer types as p53. Now the question is what is the best approach to harness it,” says senior author Joaquin Espinosa, PhD.

Read the rest of this entry